At week 72, reduction in body weight greater with tirzepatide compared with placebo<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, June 7, 2022 (HealthDay News) — For individuals with obesity, tirzepatide is associated with lasting weight loss, according to a study published online June 4 in the New England Journal of Medicine<\/em> to coincide with the annual meeting of the American Diabetes Association, held from June 3 to 7 in New Orleans.<\/p>\n Ania M. Jastreboff, M.D., Ph.D., from the Yale University School of Medicine in New Haven, Connecticut, and colleagues conducted a phase 3 trial involving 2,539 adults with a body mass index of 30 kg\/m\u00c2\u00b2 or more or 27 kg\/m\u00c2\u00b2 or more and at least one weight-related complication, excluding diabetes. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5, 10, or 15 mg) or placebo for 72 weeks in a 1:1:1:1 ratio.<\/p>\n The researchers found that the mean percentage change in weight was \u00e2\u0088\u009215.0, \u00e2\u0088\u009219.5, and \u00e2\u0088\u009220.9 percent for the 5-, 10-, and 15-mg weekly doses of tirzepatide, respectively, and \u00e2\u0088\u00923.1 percent with placebo. The percentages of participants with a weight reduction of 5 percent or more were 85, 89, and 91 percent for the 5-, 10-, and 15-mg weekly doses of tirzepatide, respectively, and 35 percent with placebo; a reduction in body weight of 20 percent or more occurred in 50 and 57 percent of participants in the 10- and 15-mg tirzepatide groups, respectively, and in 3 percent of those in the placebo group. In all prespecified cardiometabolic measures, there were improvements observed with tirzepatide.<\/p>\n “Obesity should be treated like any other chronic disease — with effective and safe approaches that target underlying disease mechanisms, and these results underscore that tirzepatide may be doing just that,” Jastreboff said in a statement.<\/p>\n Several authors disclosed financial ties to biopharmaceutical companies, including Eli Lilly, which manufactures tirzepatide and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n